Tradestie Institutional Equity Comparison Engine
LYRA vs FBRX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
FBRX Overall Edge
FBRX Captures Institutional Edge (3โ0 Pillars ยท 7โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Forte Biosciences, Inc. Common Stock (FBRX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, LYRA trades at N/M Forward P/E with -25032.0% operating margin (-87.2% YoY revenue) versus FBRX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, LYRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against FBRX sits in UNCLASSIFIED (3rd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
LYRA N/M vs FBRX N/M Fwd P/E
Growth & Margin Winner
FBRX
Op Margin -25032.0% vs 0.0% ยท YoY -87.2% vs +0.0%
Momentum & Technical Winner
FBRX
1Y -94.3% vs +580.4% ยท 52W Pos 1% vs 100%
Options & Structure Winner
FBRX
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (3rd %ile IV)
LYRA
NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap
$2.3M
1M Return
-62.5%
1Y Return
-94.34%
Forward P/E
N/M
Unified AI Score
52.2 / 100
HOLD
Tech 60.0
Fund 56.0
Flow 50.0
Mom 59.0
FBRX
NASDAQ
Forte Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$76.99
+0.03% 1D
Market Cap
$1.6B
1M Return
+0.44%
1Y Return
+580.42%
Forward P/E
N/M
Unified AI Score
52.7 / 100
HOLD
Tech 49.0
Fund 51.0
Flow 62.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
LYRA -94.34%
FBRX +580.42%
Spread: +235.54 pp (FBRX Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | LYRA Revenue | FBRX Revenue | LYRA Op. Margin | FBRX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2017 | N/A | $0M | N/A | -91775.6% | FBRX |
| FY2018 | N/A | $20M | N/A | -254.2% | FBRX |
| FY2019 | N/A | $0M | N/A | -11288.9% | FBRX |
| FY2021 | $0M | N/A | -15303.5% | N/A | LYRA |
| FY2022 | $0M | N/A | -4131.0% | N/A | LYRA |
| FY2023 | $0M | N/A | -4308.1% | N/A | LYRA |
| FY2024 | $0M | N/A | -6280.8% | N/A | LYRA |
| FY2025 | $0M | N/A | -7794.5% | N/A | LYRA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | LYRA | FBRX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.3M | $1.6B | Larger Scale | FBRX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -87.2% | +0.0% | Higher Growth | FBRX |
| Operating Margin (TTM) Profitability | -25032.0% | 0.0% | Higher Margin | FBRX |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -404.5% | -62.3% | Higher ROE | FBRX |
| 52-Week Range Position Momentum | 1% ($0โ$38) | 100% ($10โ$77) | Stronger Trend | FBRX |
| Beta / 30D Volatility Risk Regime | 0.33ฮฒ ยท 248% Vol | 1.09ฮฒ ยท 3% Vol | Lower Realized Risk | FBRX |
| Unified Institutional Score Composite Signal | 52.2 / 100 (HOLD) | 52.7 / 100 (HOLD) | Higher Composite | FBRX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full LYRA vs FBRX Buy Guide
LYRA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
FBRX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
3rd %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither LYRA nor FBRX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.